MY177940A - Transmucosal delivery of tocotrienol - Google Patents
Transmucosal delivery of tocotrienolInfo
- Publication number
- MY177940A MY177940A MYPI2015000856A MYPI2015000856A MY177940A MY 177940 A MY177940 A MY 177940A MY PI2015000856 A MYPI2015000856 A MY PI2015000856A MY PI2015000856 A MYPI2015000856 A MY PI2015000856A MY 177940 A MY177940 A MY 177940A
- Authority
- MY
- Malaysia
- Prior art keywords
- tocotrienol
- transmucosal delivery
- muscle soreness
- delivery
- present
- Prior art date
Links
- GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 title abstract 2
- 229930003802 tocotrienol Natural products 0.000 title abstract 2
- 239000011731 tocotrienol Substances 0.000 title abstract 2
- 235000019148 tocotrienols Nutrition 0.000 title abstract 2
- 208000000112 Myalgia Diseases 0.000 abstract 2
- 208000015001 muscle soreness Diseases 0.000 abstract 2
- 201000004384 Alopecia Diseases 0.000 abstract 1
- 206010014476 Elevated cholesterol Diseases 0.000 abstract 1
- 206010014486 Elevated triglycerides Diseases 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 206010020880 Hypertrophy Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000009787 cardiac fibrosis Effects 0.000 abstract 1
- 230000003111 delayed effect Effects 0.000 abstract 1
- 230000037080 exercise endurance Effects 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 230000003676 hair loss Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 230000000087 stabilizing effect Effects 0.000 abstract 1
- 150000003626 triacylglycerols Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2012904937A AU2012904937A0 (en) | 2012-11-13 | Sublingual and buccal delivery of tocotrienol derivatives as therapeutic agents | |
| AU2012905406A AU2012905406A0 (en) | 2012-12-11 | Sublingual and buccal delivery of tocotrienol derivatives as therapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY177940A true MY177940A (en) | 2020-09-28 |
Family
ID=50730398
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2015000856A MY177940A (en) | 2012-11-13 | 2013-11-13 | Transmucosal delivery of tocotrienol |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US10675265B2 (OSRAM) |
| EP (1) | EP2919777B1 (OSRAM) |
| JP (3) | JP6460998B2 (OSRAM) |
| KR (1) | KR20150082109A (OSRAM) |
| CN (2) | CN104582700B (OSRAM) |
| AU (1) | AU2013344817B2 (OSRAM) |
| BR (1) | BR112015010703B1 (OSRAM) |
| CA (1) | CA2891164C (OSRAM) |
| DK (1) | DK2919777T3 (OSRAM) |
| ES (1) | ES2778065T3 (OSRAM) |
| IL (1) | IL238727A0 (OSRAM) |
| IN (1) | IN2015DN04006A (OSRAM) |
| MY (1) | MY177940A (OSRAM) |
| NZ (1) | NZ628963A (OSRAM) |
| PE (1) | PE20151518A1 (OSRAM) |
| PH (1) | PH12015501048A1 (OSRAM) |
| PL (1) | PL2919777T3 (OSRAM) |
| PT (1) | PT2919777T (OSRAM) |
| RU (1) | RU2015120181A (OSRAM) |
| SG (1) | SG11201503640WA (OSRAM) |
| WO (1) | WO2014075135A1 (OSRAM) |
| ZA (1) | ZA201504191B (OSRAM) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9897565B1 (en) | 2012-09-11 | 2018-02-20 | Aseko, Inc. | System and method for optimizing insulin dosages for diabetic subjects |
| US9171343B1 (en) | 2012-09-11 | 2015-10-27 | Aseko, Inc. | Means and method for improved glycemic control for diabetic patients |
| NZ628963A (en) * | 2012-11-13 | 2017-02-24 | Gordagen Pharmaceuticals Pty Ltd | Transmucosal delivery of tocotrienol |
| US9898585B2 (en) | 2014-01-31 | 2018-02-20 | Aseko, Inc. | Method and system for insulin management |
| US9486580B2 (en) | 2014-01-31 | 2016-11-08 | Aseko, Inc. | Insulin management |
| US11081226B2 (en) | 2014-10-27 | 2021-08-03 | Aseko, Inc. | Method and controller for administering recommended insulin dosages to a patient |
| JP6989262B2 (ja) | 2014-10-27 | 2022-01-05 | アセコー インコーポレイテッド | 皮下外来患者管理 |
| JP2018522950A (ja) * | 2015-08-11 | 2018-08-16 | 杉山 理 | 血液循環の改善及びミトコンドリアエネルギー産生の維持のためのシステム並びに方法 |
| AU2016308953B2 (en) | 2015-08-20 | 2020-09-10 | Glytec, Llc | Diabetes management therapy advisor |
| WO2019032685A1 (en) * | 2017-08-08 | 2019-02-14 | Robert John Petcavich | FORMULATIONS FOR THE CONTRIBUTION OF TREHALOSE STIMULATING AUTOPHAGIA |
| CA3201035A1 (en) * | 2020-12-04 | 2022-06-09 | Glenn Tong | Transmucosal delivery of tocotrienols |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993009777A1 (en) * | 1991-11-22 | 1993-05-27 | Lipogenics, Inc. | Tocotrienols and tocotrienol-like compounds and methods for their use |
| JPH0892050A (ja) | 1994-09-27 | 1996-04-09 | Lion Corp | 消臭剤及び口腔用組成物 |
| JP4271742B2 (ja) | 1997-08-07 | 2009-06-03 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 免疫機能改善剤 |
| US6264981B1 (en) | 1999-10-27 | 2001-07-24 | Anesta Corporation | Oral transmucosal drug dosage using solid solution |
| CA2403977C (en) * | 2000-03-31 | 2009-09-01 | Eisai Co., Ltd. | .gamma.-tocotrienol-containing diuretics |
| JP2001342133A (ja) | 2000-03-31 | 2001-12-11 | Eisai Co Ltd | γ―トコトリエノール含有利尿剤 |
| JP2002037727A (ja) | 2000-07-26 | 2002-02-06 | Eisai Co Ltd | 脂溶性薬物を配合した速崩性固形製剤及びその製造方法 |
| JP4693140B2 (ja) | 2000-10-06 | 2011-06-01 | 富士化学工業株式会社 | トコトリエノール含有医薬用剤 |
| US6608103B2 (en) * | 2001-02-08 | 2003-08-19 | Fuji Chemical Industry Co., Ltd. | Inhibitor for neovasculation, cell multiplication, lumen formation and FGF |
| JP4447198B2 (ja) | 2001-02-08 | 2010-04-07 | 富士化学工業株式会社 | トコトリエノールを有効成分とする血管新生阻害剤、細胞増殖阻害剤、管腔形成阻害剤及びｆｇｆ阻害剤並びに食品或いは食品添加物 |
| JP4903558B2 (ja) | 2003-02-14 | 2012-03-28 | ヘンリー エム．ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディシン，インコーポレイティド | ガンマ−トコトリエノールによる放射線防護 |
| WO2005009135A1 (en) * | 2003-04-10 | 2005-02-03 | Barrie Tan | Annatto extract compositions including tocotrienols and tocopherols and methods of use |
| US20050209315A1 (en) * | 2004-03-20 | 2005-09-22 | Papas Andreas M | Bioavailable nutritional supplement and method of treatment of malabsorption |
| EP1748774B1 (en) * | 2004-05-26 | 2010-12-15 | KGK Synergize, Inc. | Compositions comprising flavonoids and tocotrienols and uses thereof |
| CN1775289B (zh) | 2004-11-15 | 2011-08-24 | 杭州赛诺菲民生健康药业有限公司 | 多维生素口腔崩解片制剂及其制备方法 |
| EP2271347B1 (en) | 2008-03-28 | 2016-05-11 | Hale Biopharma Ventures, Llc | Administration of benzodiazepine compositions |
| WO2009126866A2 (en) * | 2008-04-10 | 2009-10-15 | Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Delta-tocotrienol as a radioprotective countermeasure agent |
| WO2010144943A1 (en) | 2009-05-20 | 2010-12-23 | Ozpharma Pty Ltd | Buccal and/or sublingual therapeutic formulation |
| JP2012531411A (ja) | 2009-06-25 | 2012-12-10 | アンペア ライフ サイエンシーズ，インコーポレイテッド | トコトリエノールまたはトコトリエノール濃縮抽出物を用いた広汎性発達障害の処置 |
| CA2772294C (en) * | 2009-08-26 | 2018-08-21 | Guy M. Miller | Methods for the prevention and treatment of cerebral ischemia |
| EP2519232A1 (en) | 2009-12-31 | 2012-11-07 | Edison Pharmaceuticals, Inc. | Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones |
| JP2013523816A (ja) | 2010-04-06 | 2013-06-17 | エジソン ファーマシューティカルズ， インコーポレイテッド | 毛細血管拡張性運動失調症の治療 |
| US20120295985A1 (en) | 2010-11-19 | 2012-11-22 | Miller Guy M | Methods for improving blood glucose control |
| US8951566B2 (en) | 2011-02-18 | 2015-02-10 | Sai Ying Ko | Process for preparing products comprising stabilised actives and compositions comprising same |
| EP3415139B8 (en) * | 2011-06-14 | 2022-05-18 | Neurelis, Inc. | Administration of benzodiazepine |
| NZ628963A (en) * | 2012-11-13 | 2017-02-24 | Gordagen Pharmaceuticals Pty Ltd | Transmucosal delivery of tocotrienol |
-
2013
- 2013-11-13 NZ NZ628963A patent/NZ628963A/en unknown
- 2013-11-13 MY MYPI2015000856A patent/MY177940A/en unknown
- 2013-11-13 BR BR112015010703-6A patent/BR112015010703B1/pt active IP Right Grant
- 2013-11-13 US US14/435,607 patent/US10675265B2/en active Active
- 2013-11-13 AU AU2013344817A patent/AU2013344817B2/en active Active
- 2013-11-13 DK DK13854440.8T patent/DK2919777T3/da active
- 2013-11-13 CN CN201380022566.8A patent/CN104582700B/zh active Active
- 2013-11-13 KR KR1020147022626A patent/KR20150082109A/ko not_active Withdrawn
- 2013-11-13 CN CN202011457257.1A patent/CN112451518B/zh active Active
- 2013-11-13 CA CA2891164A patent/CA2891164C/en active Active
- 2013-11-13 PT PT138544408T patent/PT2919777T/pt unknown
- 2013-11-13 ES ES13854440T patent/ES2778065T3/es active Active
- 2013-11-13 SG SG11201503640WA patent/SG11201503640WA/en unknown
- 2013-11-13 EP EP13854440.8A patent/EP2919777B1/en active Active
- 2013-11-13 WO PCT/AU2013/001310 patent/WO2014075135A1/en not_active Ceased
- 2013-11-13 JP JP2015540965A patent/JP6460998B2/ja active Active
- 2013-11-13 PL PL13854440T patent/PL2919777T3/pl unknown
- 2013-11-13 PE PE2015000622A patent/PE20151518A1/es not_active Application Discontinuation
- 2013-11-13 RU RU2015120181A patent/RU2015120181A/ru not_active Application Discontinuation
-
2015
- 2015-05-10 IL IL238727A patent/IL238727A0/en unknown
- 2015-05-11 PH PH12015501048A patent/PH12015501048A1/en unknown
- 2015-05-11 IN IN4006DEN2015 patent/IN2015DN04006A/en unknown
- 2015-06-10 ZA ZA2015/04191A patent/ZA201504191B/en unknown
-
2018
- 2018-09-21 JP JP2018177662A patent/JP6978392B2/ja active Active
-
2020
- 2020-04-23 US US15/929,297 patent/US11331302B2/en active Active
- 2020-10-09 JP JP2020171008A patent/JP2021008509A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015501048A1 (en) | Transmucosal delivery of tocotrienol | |
| MY187988A (en) | Composition for treating hyperlipidemia comprising oxyntomodulin derivative | |
| EA201190219A1 (ru) | Способы и композиции для лечения ишемических состояний и состояний, связанных с функцией митохондрий | |
| EA201290836A1 (ru) | Связанные бис-арильные арилтриазолоны и их применение | |
| WO2012088266A3 (en) | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 | |
| EA201300869A1 (ru) | Морфинановые соединения | |
| MX2013006040A (es) | Antagonistas del receptor de acido lisofosfatidico y su uso en el tratamiento de fibrosis. | |
| WO2013003112A9 (en) | Methods and compositions for treatment of cancer and autoimmune disease | |
| EA201490228A1 (ru) | Новые производные трифторметилоксадиазола и их применение для лечения заболевания | |
| UY32820A (es) | Composiciones dermatologicas de antagonistas del receptor dp2 | |
| EA201100691A1 (ru) | Антагонисты рецепторов лизофосфатидной кислоты | |
| EP2853543A8 (en) | Anti-blys antibody | |
| NO20090623L (no) | Forbindelser for behandling av proliferative lidelser | |
| UA114705C2 (uk) | Андрогенна композиція для лікування офтальмологічного захворювання | |
| MX360554B (es) | Composiciones que comprenden y metodos que utilizan inhibidores de co-transportadores de glucosa-sodio 1 y 2. | |
| JP2016503407A5 (OSRAM) | ||
| EA201290808A1 (ru) | Замещенные конденсированные производные имидазола, фармацевтические композиции и способы их применения | |
| EA201291167A1 (ru) | Замещенные гетероциклилбензилпиразолы и их применение | |
| DK2714888T3 (da) | Rekombinant gær | |
| MY152951A (en) | Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine, their preparation and their therapeutic application | |
| EP4137147A3 (en) | Uses of abaloparatide in reducing fracture risk | |
| EA201490268A1 (ru) | Производные циклопропиламида, направленно действующие на гистаминовый н3-рецептор | |
| GB201213484D0 (en) | Pharmaceutical compositions comprising 15-OHEPA and methods of using the same | |
| EP2575456A4 (en) | COMPOSITIONS AND METHODS FOR TREATING PRESENTATIONS | |
| UA105285C2 (uk) | Тверда фармацевтична композиція раміприлу і безилату амлодипіну і її отримання |